Abstract
To understand the genetic basis of heart failure (HF) in the Japanese population, we performed genome-wide association studies (GWASs) comprising 16,251 all-cause HF cases, 4,254 HF with reduced ejection fraction cases, 7,154 HF with preserved ejection fraction cases, and 11,122 non-ischemic HF cases among 213,828 individuals and identified five novel loci. A subsequent cross-ancestry meta-analysis and multi-trait analysis of the GWAS data identified 19 novel loci in total. Among these susceptibility loci, a common non-coding variant in TTN (rs1484116) was associated with reduced cardiac function and worse long-term mortality. We leveraged the HF meta-GWASs along with cardiac function-related GWASs to develop a polygenic risk score (PRS) for HF. The PRS successfully identified early-onset HF and those with an increased risk of long-term HF mortality. Our results shed light on the shared and distinct genetic basis of HF between Japanese and European populations and improve the clinical value of HF genetics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the Japan Agency for Medical Research and Development (AMED) (JP24bm1423005 to K.I, nos. JP24ek0210164, JP24tm0524004, and JP24tm0624002 to K.I., S.N., and I.K., and nos. JP24km0405209 and JP20ek0109487 to K. Miyazawa, K. I, S. K., S. N., H. Akazawa, and I. K.), Japan Foundation for Applied Enzymology (to N.E), the Japan Society for the Promotion of Science (to N. E. and K. I.), and the Research Funding for Longevity Sciences from NCGG (24-15 to K.O. and K.I.). BBJ was supported by the Tailor-Made Medical Treatment Program of the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) and AMED under grant numbers JP17km0305002, JP17km0305001, and JP24tm0624002.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study was approved by the appropriate Institutional Review Board at each facility and the informed consent was obtained from all participants in each study. We obtained approval from ethics committees of RIKEN Center for Integrative Medical Sciences and the Institute of Medical Sciences, The University of Tokyo.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
